Millennium Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Millennium Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-52,000	Closed	-$8.12M	–	6781
2020 Q4	$8.12M	Buy	+52,000	New	+$6.68M	0.01%	1969
2020 Q2	–	Sell	-100,900	Closed	-$9.06M	–	4813
2020 Q1	$9.06M	Buy	100,900 +900	+0.9%	+$88.3K	0.02%	924
2019 Q4	$10.8M	Sell	100,000 -50,000	-33%	-$5.35M	0.01%	1316
2019 Q3	$14.7M	Sell	150,000 -51,300	-25%	-$5.78M	0.02%	996
2019 Q2	$26.4M	Buy	201,300 +151,100	+301%	+$19.5M	0.04%	630
2019 Q1	$6.79M	Sell	50,200 -109,800	-69%	-$13.7M	0.01%	1546
2018 Q4	$15.6M	Sell	160,000 -60,000	-27%	-$7.09M	0.02%	835
2018 Q3	$30.6M	Buy	+220,000	New	+$27.6M	0.04%	629
2018 Q2	–	Sell	-50,000	Closed	-$5.57M	–	4335
2018 Q1	$5.57M	Buy	+50,000	New	+$5.98M	0.01%	1732
2016 Q3	–	Sell	-50,000	Closed	-$5.84M	–	3744
2016 Q2	$5.84M	Buy	+50,000	New	+$7.09M	0.01%	1160
2014 Q1	–	Sell	-69,400	Closed	-$9.22M	–	4026
2013 Q4	$9.22M	Buy	69,400 +3,400	+5%	+$408K	0.03%	765
2013 Q3	$7.67M	Buy	66,000 +62,000	+1,550%	+$6.8M	0.02%	861
2013 Q2	$369K	Buy	+4,000	New	+$385K	﹤0.01%	2482

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Millennium Management's ALXN Position: Q3 2021 in Review

Millennium Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 4,829,380 shares — an estimated $887M sold.

Millennium Management first reported a position in ALXN in Q2 2013 and held it in 32 quarters. The position peaked at $887M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Millennium Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Millennium Management sold 4,829,380 Alexion Pharmaceuticals shares in Q3 2021, an estimated $887M.
Millennium Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 32 quarters.
Millennium Management's Alexion Pharmaceuticals position peaked at $887M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Millennium Management's 13F filing for Q3 2021, filed 15 Nov 2021.